Alliance A061202:伊沙佐米、泊马度胺和地塞米松治疗首次复发的来那度胺难治性多发性骨髓瘤患者
本研究为随机2期研究,评估口服蛋白酶体抑制剂伊沙佐米联合泊马度胺和地塞米松(IXA-POM-DEX)对比泊马度胺和地塞米松(POM-DEX)在来那度胺难治性首次复发多发性骨髓瘤患者中的疗效与安全性。IXA-POM-DEX组总缓解率为63.2%,POM-DEX组为43.6%;≥非常好的部分缓解率分别为28.9%和5.1%(P=0.0063)。中位无进展生存期IXA-POM-DEX组为20.3个月,POM-DEX组为7.5个月(HR 0.437)。
要点
- IXA-POM-DEX组总缓解率63.2%,POM-DEX组43.6%。
- ≥非常好的部分缓解率IXA-POM-DEX组28.9% vs POM-DEX组5.1%(P=0.0063)。
- 中位无进展生存期IXA-POM-DEX组20.3个月 vs POM-DEX组7.5个月(HR 0.437)。
核心结论
- 数据支持在3期研究中进一步比较该全口服三药方案与当前标准三药方案用于来那度胺难治性首次复发患者。
研究设计与样本
- 随机2期研究,评估伊沙佐米联合泊马度胺和地塞米松(IXA-POM-DEX)对比泊马度胺和地塞米松(POM-DEX)在来那度胺难治性首次复发多发性骨髓瘤患者中的疗效与安全性。
主要发现
- 总缓解率POM-DEX组为43.6%,IXA-POM-DEX组为63.2%。
- 达到至少非常好的部分缓解的比例IXA-POM-DEX组为28.9%,POM-DEX组为5.1%(P=0.0063)。
- 中位无进展生存期POM-DEX组为7.5个月(95%CI 4.8-13.6个月),IXA-POM-DEX组为20.3个月(95%CI 7.7-26.0个月;风险比0.437;90%置信上限=0.657)。
- 从双药组交叉至三药组的30例合格患者中有26例,其总缓解率为23.1%,中位无进展生存期为5.6个月。
- 两组总生存期相似;三药组血液学毒性更多,非血液学不良事件两组相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Optimal therapy for the growing number of patients with lenalidomide (LEN)-refractory multiple myeloma in their first relapse remains poorly defined. We therefore undertook a randomized phase 2 study to evaluate the efficacy and safety of combining the oral proteasome inhibitor ixazomib (IXA) with pomalidomide (POM) and dexamethasone (DEX) in this patient population. The overall response rate (ORR) for POM-DEX was 43.6%, and for IXA-POM-DEX, it was 63.2%. The depth of response, measured by the attainment of at least a very good partial response, favored triplet therapy over doublet therapy (28.9% vs 5.1%; P = .0063). A preplanned interim analysis after 75% of the progression events had occurred demonstrated an improvement in progression-free survival (PFS) that favored IXA-POM-DEX and that crossed the predefined boundary of superiority, leading to release of the study results. With additional follow-up, the median PFS for POM-DEX was 7.5 months (95% confidence interval [CI], 4.8-13.6 months) vs 20.3 months for IXA-POM-DEX (95% CI, 7.7-26.0 months; hazard ratio, 0.437; upper 90% bound = 0.657). The ORR and median PFS for 26 of 30 eligible patients who crossed over from the doublet to the triplet therapy at disease progression was 23.1% and 5.6 months, respectively. Overall survival was similar between the 2 groups. More hematologic toxicities were seen with the triplet therapy, but nonhematologic adverse events were similar between the 2 arms. Our data support further testing of this all-oral triplet therapy in comparison with current standard triplet therapy in the context of phase 3 studies for patients with LEN-refractory disease at first relapse. This trial was registered at www.clinicaltrials.gov as #NCT02004275.
引用
- Voorhees P, Suman V, Efebera Y, et al. Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse. Blood Adv. 2024. PMID: 39058954. doi:10.1182/bloodadvances.2024013623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。